Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: Results of a phase i, randomized, multiple-dose study in healthy Korean men and women

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 197-210

  Kim, Mi Jo ^a   Lim, Hyeong Seok ^a   Jin, Seokjoon ^b   Jung, Jin Ah ^c   Noh, Yook Hwan ^a   Kim, Yo Han ^a   Bae, Kyun Seop ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Carbonic anhydrase; COX 2 inhibitor; NSIADs; Prostacyclin; Thromboxane

Indexed keywords

CREATININE; CYCLOOXYGENASE 2 INHIBITOR; POLMACOXIB; PROSTACYCLIN; PROSTAGLANDIN E2; THROMBOXANE; THROMBOXANE B2; FURAN DERIVATIVE; SULFONAMIDE;

ADULT; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FURANS; HUMANS; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920768692     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.07.007     Document Type: Article

References (22)

1. Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther. 2008;118:161-180.
2. Decker SL, Schappert SM, Sisk JE. Use of medical care for chronic conditions. Health Aff (Millwood). 2009;28:26-35.
3. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care. 2002;8:S383-S391.
4. Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85-94.
5. Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol. 2008;59 (Suppl 2):117-133.
6. Pilotto A, Sancarlo D, Addante F, et al. Non-steroidal anti-inflammatory drug use in the elderly. Surg Oncol. 2010;19:167-172.
7. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756-1764.
8. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
9. Aljadhey H, Tu W, Hansen RA, et al. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2012;12:93.
10. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470-479.
11. Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007;28:106-110.
12. Ruan CH, So SP, Ruan KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease. Life Sci. 2011;88:24-30.
13. Vane JR. Biomedicine. Back to an aspirin a day? Science. 2002;296:474-475.
14. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost. 2007;5:2376-2385.
15. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1998;289:735-741.
16. Puscas I, Coltau M, Pasca R. Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. J Pharmacol Exp Ther. 1996;277:1464-1466.
17. Skarke C, Alamuddin N, Lawson JA, et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal antiinflammatory drug CG100649. Clin Pharmacol Ther. 2012;91:986-993.
18. CrystalGenomics Inc. Investigator's Brochure. Product: CG100649, Version 4.0. Seoul, South Korea: CrystalGenomics, Inc; 2009:14-19.
19. Laufer S, Luik S. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors. Methods Mol Biol. 2010;644:91-116.
20. Gierse J, Nickols M, Leahy K, et al. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol. 2008;588:93-98.
21. Nylander S, Johansson K, Van Giezen JJ, Lindahl TL. Evaluation of platelet function, a method comparison. Platelets. 2006;17:49-55.
22. Conroy CW, Maren TH. The effect of temperature on the binding of sulfonamides to carbonic anhydrase isoenzymes I, II and IV. Mol Pharmacol. 1995;48:486-491.